Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CES2 | O00748 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 4/20 | 0.38 |
| ▸ | CA2 | P00918 | 4/20 | 0.38 |
| ▸ | CA9 | Q16790 | 4/20 | 0.38 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.38 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.38 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.38 |
| ▸ | NAAA | Q02083 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15208422 | 1.00 | MEN1 (0.48) | MEN1THRBHTTKMT2AMAPT | |
| SCHEMBL7045692 | 1.00 | MEN1 (0.48) | MEN1THRBHTTKMT2AMAPT | |
| SCHEMBL7044920 | 1.00 | MEN1 (0.48) | MEN1THRBHTTKMT2AMAPT | |
| SCHEMBL7044023 | 1.00 | MEN1 (0.48) | MEN1THRBHTTKMT2AMAPT | |
| SCHEMBL7043779 | 1.00 | MEN1 (0.48) | MEN1THRBHTTKMT2AMAPT | |
| SCHEMBL7045534 | 1.00 | MEN1 (0.48) | MEN1THRBHTTKMT2AMAPT | |
| SCHEMBL7045822 | 1.00 | MEN1 (0.48) | MEN1THRBHTTKMT2AMAPT | |
| SCHEMBL7044520 | 1.00 | MEN1 (0.48) | MEN1THRBHTTKMT2AMAPT | |
| SCHEMBL7045509 | 1.00 | MEN1 (0.48) | MEN1THRBHTTKMT2AMAPT | |
| SCHEMBL4396265 | 0.98 | MEN1 (0.50) | MEN1THRBHTTKMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030064954-A1 | Cationic amphiphilic 1,4-dihydropyridine derivatives useful for delivery of nucleotide containing compounds | SPONDULI SERVICES, LTD. (AU) | 2003-04-03 | — | — | US | claimed |
| EP-1261731-A1 | CATIONIC AMPHIPHILIC 1,4-DIHYDROPYRIDINE DERIVATIVES USEFUL FOR DELIVERY OF NUCLEOTIDE CONTAINING COMPOUNDS | Urtti, Arto (FI) | 2002-12-04 | — | — | EP | claimed |
| WO-2001062946-A1 | CATIONIC AMPHIPHILIC 1,4-DIHYDROPYRIDINE DERIVATIVES USEFUL FOR DELIVERY OF NUCLEOTIDE CONTAINING COMPOUNDS | URTTI ARTO (FI) | 2001-08-30 | — | — | WO | claimed |
| US-20030064954-A1 | Cationic amphiphilic 1,4-dihydropyridine derivatives useful for delivery of nucleotide containing compounds | SPONDULI SERVICES, LTD. (AU) | 2003-04-03 | — | — | US | disclosed |
| EP-1261731-A1 | CATIONIC AMPHIPHILIC 1,4-DIHYDROPYRIDINE DERIVATIVES USEFUL FOR DELIVERY OF NUCLEOTIDE CONTAINING COMPOUNDS | Urtti, Arto (FI) | 2002-12-04 | — | — | EP | disclosed |
| WO-2001062946-A1 | CATIONIC AMPHIPHILIC 1,4-DIHYDROPYRIDINE DERIVATIVES USEFUL FOR DELIVERY OF NUCLEOTIDE CONTAINING COMPOUNDS | URTTI ARTO (FI) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064954-A1 | Cationic amphiphilic 1,4-dihydropyridine derivatives useful for delivery of nucleotide containing compounds | ACIN1, DNA2, KPNA1 | MEN1 2117/4885THRB 4695/4885HTT 1168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.